Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro

Bortezomib (BOZ) is a proteasome inhibitor chemotherapeutic agent utilized to treat multiple myeloma and recently offered to cure melanoma. Bortezomib-induced neuropathy is one of the dose-limiting side-effects, which can be treated with antioxidants (e.g. alpha-lipoic acid—ALA and Vitamin B1—vit B1...

Descripción completa

Detalles Bibliográficos
Autores principales: Takács, Angéla, Lajkó, Eszter, Láng, Orsolya, Istenes, Ildikó, Kőhidai, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459291/
https://www.ncbi.nlm.nih.gov/pubmed/32868799
http://dx.doi.org/10.1038/s41598-020-71138-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459291/
https://www.ncbi.nlm.nih.gov/pubmed/32868799
http://dx.doi.org/10.1038/s41598-020-71138-z

Ejemplares similares